Your browser is no longer supported. Please, upgrade your browser.
ALLO Allogene Therapeutics, Inc. daily Stock Chart
Allogene Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own2.80% Shs Outstand120.72M Perf Week9.21%
Market Cap3.10B Forward P/E- EPS next Y-2.59 Insider Trans0.00% Shs Float51.17M Perf Month0.78%
Income-154.10M PEG- EPS next Q-0.69 Inst Own57.30% Short Float25.11% Perf Quarter-7.75%
Sales- P/S- EPS this Y73.60% Inst Trans1.53% Short Ratio20.36 Perf Half Y-5.30%
Book/sh6.06 P/B4.24 EPS next Y-34.20% ROA-20.90% Target Price36.82 Perf Year-16.19%
Cash/sh4.15 P/C6.19 EPS next 5Y- ROE-23.20% 52W Range21.25 - 33.80 Perf YTD-1.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.64% Beta-
Dividend %- Quick Ratio15.30 Sales past 5Y- Gross Margin- 52W Low21.46% ATR1.00
Employees190 Current Ratio15.30 Sales Q/Q- Oper. Margin- RSI (14)63.47 Volatility4.51% 4.17%
OptionableYes Debt/Eq0.00 EPS Q/Q-31.50% Profit Margin- Rel Volume1.04 Prev Close25.72
ShortableYes LT Debt/Eq0.00 EarningsMar 06 BMO Payout- Avg Volume631.01K Price25.81
Recom1.90 SMA2010.75% SMA501.77% SMA200-5.71% Volume380,871 Change0.35%
Dec-18-19Initiated JMP Securities Mkt Outperform $37
Nov-04-19Initiated Canaccord Genuity Buy $36
Aug-09-19Initiated BTIG Research Buy $37
Jun-05-19Initiated ROTH Capital Neutral $26
May-31-19Initiated Guggenheim Neutral
May-23-19Initiated Stifel Hold
Mar-29-19Initiated Piper Jaffray Overweight $50
Mar-15-19Initiated Raymond James Outperform
Mar-14-19Initiated William Blair Outperform
Nov-05-18Initiated JP Morgan Neutral $29
Nov-05-18Initiated Jefferies Buy
Nov-05-18Initiated Goldman Buy
Nov-05-18Initiated Cowen Outperform
Feb-19-20 08:30AM  Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020 GlobeNewswire
Feb-06-20 08:30AM  Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule GlobeNewswire +6.83%
Jan-13-20 06:00AM  Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma GlobeNewswire
Jan-02-20 08:30AM  Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-20-19 05:16PM  Is Allogene Therapeutics, Inc. (ALLO) A Good Stock To Buy? Insider Monkey
Nov-11-19 08:30AM  Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule GlobeNewswire
Nov-06-19 09:02AM  Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T Pipeline at 61st American Society of Hematology Annual Meeting GlobeNewswire -6.40%
Nov-05-19 07:30AM  Allogene Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
06:28AM  Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications GlobeNewswire
Oct-29-19 08:30AM  Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019 GlobeNewswire
Oct-25-19 11:12AM  Is Allogene Therapeutics, Inc. (ALLO) A Good Stock To Buy? Insider Monkey
Oct-18-19 11:22AM  New Gilead CFO: Let's Make a Deal
Oct-03-19 05:53PM  Moderna, Allogene Have Disappointed Investors
Sep-19-19 08:00AM  Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies GlobeNewswire
06:59AM  When Will Allogene Therapeutics, Inc. (NASDAQ:ALLO) Come Back To Market? Simply Wall St.
Sep-18-19 05:33PM  Why Roche's former CEO thinks Pfizer and this cancer-fighting company may be on to something American City Business Journals
Sep-03-19 08:30AM  Allogene Therapeutics Announces September 2019 Investor Conference Schedule GlobeNewswire
Aug-20-19 10:00AM  Flush with cash after Gilead deal, founder pivots to real estate for his companies American City Business Journals
Aug-07-19 11:24PM  Allogene Therapeutics Inc (ALLO) Q2 2019 Earnings Call Transcript Motley Fool
07:30AM  Allogene Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-05-19 06:00AM  Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer GlobeNewswire
Jul-29-19 08:30AM  Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019 GlobeNewswire
Jul-16-19 08:00AM  Tishman Speyer launches life sciences division, starts with South Boston project American City Business Journals
Jun-22-19 07:30AM  Senator Dianne Feinsteins Husband Sold Nvidia Stock, Bought FireEye
Jun-04-19 07:45AM  Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T) Therapy GlobeNewswire
Jun-03-19 11:00AM  Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO American City Business Journals
May-29-19 08:30AM  Allogene Therapeutics Announces June 2019 Investor Conference Schedule GlobeNewswire
May-07-19 10:24PM  Allogene Therapeutics Inc (ALLO) Q1 2019 Earnings Call Transcript Motley Fool
07:53AM  Allogene Therapeutics: 1Q Earnings Snapshot Associated Press
07:30AM  Allogene Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
May-05-19 09:19AM  2 Big Biotech Stock Upgrades: Can They Reach These Targets? Motley Fool
May-01-19 08:30AM  Allogene Therapeutics Announces Expansion of Scientific Advisory Board GlobeNewswire
Apr-30-19 08:30AM  Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019 GlobeNewswire
Apr-15-19 08:00AM  Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T Therapy) in Multiple Myeloma GlobeNewswire
Apr-03-19 04:30PM  Allogene Therapeutics Announces April 2019 Investor Conference Schedule GlobeNewswire
Apr-01-19 01:00PM  Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting GlobeNewswire
Mar-14-19 10:14AM  All You Need To Know About Allogene Therapeutics, Inc.s (NASDAQ:ALLO) Financial Health Simply Wall St.
Mar-08-19 08:00AM  Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
06:30AM  Allogene Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-20-19 03:46PM  Meet Facebook's new neighbor: Cutting-edge cell therapy company lands big East Bay space American City Business Journals
08:00AM  Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T) Therapies GlobeNewswire
Feb-08-19 10:40AM  4 Disruptive Healthcare Stocks You've Never Heard Of Motley Fool
Feb-05-19 08:00AM  Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule GlobeNewswire
Jan-29-19 09:38AM  What's next for this slow-moving Peninsula biotech IPO? American City Business Journals
Jan-28-19 08:30AM  Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T) Therapy GlobeNewswire
Jan-18-19 05:19PM  KPMG's former S.F. head Debbie Messemer lands on leading fintech's board American City Business Journals
Jan-17-19 09:37AM  East Bay accounting firms new leader says improv upped his presentation skills American City Business Journals
Jan-14-19 08:00AM  Today's Research Reports on Trending Tickers: Novavax and Allogene Therapeutics ACCESSWIRE
Jan-09-19 09:28AM  Cell therapy pioneer eyes Bay Area manufacturing American City Business Journals
Jan-02-19 01:15PM  Here are the winners and losers from Bay Area's IPO class of 2018 American City Business Journals
Dec-19-18 08:00AM  Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-06-18 08:54PM  Cambridge's Moderna sets record with $604M IPO American City Business Journals -11.12%
06:24AM  Here's how Moderna's IPO stacks up against others in biotech American City Business Journals
Dec-03-18 07:45PM  Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia GlobeNewswire
10:30AM  Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting GlobeNewswire
Nov-29-18 04:05PM  Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech Investor's Business Daily
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-05-18 08:00AM  Allogene Therapeutics Announces November 2018 Investor Conference Schedule GlobeNewswire
Nov-01-18 09:26AM  Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting Business Wire +12.24%
Oct-31-18 03:34PM  Strong IPO pace continued in October but some cracks are showing American City Business Journals
Oct-25-18 07:30AM  How This Underfollowed $6 Biotech Could Be Worth $10 ACCESSWIRE
Oct-22-18 11:57AM  Weekly CEO Buys Highlight
Oct-17-18 08:15PM  Allogene Therapeutics Inc (ALLO) President and CEO David D Chang Bought $720,000 of Shares
Oct-15-18 04:30PM  Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-12-18 01:15PM  Nasdaq Welcomes Allogene Therapeutics, Inc. (Nasdaq: ALLO) To The Nasdaq Stock Market GlobeNewswire +7.24%
Oct-10-18 11:21AM  Allogene's IPO: What You Need To Know Benzinga
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company has a research collaboration agreement with Stanford University to investigate a novel nucleic acid delivery system developed by Stanford researchers to deliver intracellular RNA or DNA into lymphocytes, including T cells. The company was founded in 2017 and is headquartered in South San Francisco, California.